
Ascendis Pharma (ASND): Rare-Disease Growth Is Accelerating
Ascendis Pharma is transitioning into a commercial rare-disease platform, with Q2 2026 product revenue up 105% year over year and YORVIPATH emerging as the main growth engine. Valuation and execution risks remain, but the company’s expanding portfolio and strong launch momentum support a Buy view.

